newsfilter
← Latest News
Business Wire·

Rallybio to Discontinue Development of RLYB212 for Prevention of FNAIT

– RLYB212 Phase 2 PK Results Did Not Achieve Target Concentrations, Including Minimum Target Concentration Required for Efficacy – – RLYB116 Confirmatory PK/PD Study to Initiate in 2Q 2025, with Data in 2H 2025